Targeting PARP1: A Promising Approach for Next-Generation Poly (ADP-ribose) Polymerase Inhibitors
Open Access
- 12 June 2025
- journal article
- review article
- Published by Springer Nature in Current Breast Cancer Reports
- Vol. 17 (1) , 1-14
Abstract
Limitations of Poly (ADP‒ribose) Polymerase (PARP) Inhibitors: PARPis have demonstrated efficacy in BRCA-mutated cancers deficient in homologous recombination repair. Furthermore, PARPis have shown efficacy in BRCA-wild-type cancers with a homologous recombination deficiency phenotype known as BRCAness. Current clinically approved PARPis inhibit both PARP1 and PARP2, and their clinical promise is limited by toxicity, resistance, and a lack of combination partners. Recent Findings: PARP2 inhibition is associated with hematological toxicity, affecting the tolerability and efficacy of monotherapy and combination therapies. Furthermore, synthetic lethality in BRCA-mutated cancers depends mostly on PARP1, whereas PARP2 is not essential. These findings promoted the development of next-generation PARPis with greater selectivity for PARP1 than for PARP2. Summary: In this review, we discuss the next-generation PARPis that target PARP1 and show promise in terms of improved safety, tolerability, pharmacological profiles, and efficacy compared to existing clinically approved PARPis. These next-generation PARP1-selective inhibitors hold significant promises for improving the survival and outcomes of cancer patients.Keywords
Funding Information
- National Institutes of Health (P30 CA082709)
- Vera Bradley Foundation for Breast Cancer
This publication has 124 references indexed in Scilit:
- Exposure‐Response Model With Time‐Varying Predictors to Estimate the Effects of Veliparib in Combination With Carboplatin/Paclitaxel and as Monotherapy: Veliparib Phase 3 Study in BRCA ‐Mutated Advanced Breast Cancer (BROCADE3) TrialThe Journal of Clinical Pharmacology, 2022
- Correction to: Fuzuloparib: First ApprovalDrugs, 2021
- An Overview of PARP Inhibitors for the Treatment of Breast CancerTargeted Oncology, 2021
- Novel poly (ADP-ribose) polymerases inhibitor DHC-1 exhibits in vitro and in vivo anticancer activity on BRCA-deficient pancreatic cancer cellsFood and Chemical Toxicology, 2021
- Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic LethalityCancer Cell, 2019
- Mechanisms of PARP inhibitor sensitivity and resistanceDNA Repair, 2018
- Poly(ADP-ribose) polymerase-2: emerging transcriptional roles of a DNA-repair proteinCellular and Molecular Life Sciences, 2012
- A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivityDNA Repair, 2008
- NAD+-Dependent Modulation of Chromatin Structure and Transcription by Nucleosome Binding Properties of PARP-1Cell, 2004
- The PARP superfamilyBioEssays, 2004